GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLB Pharmaceutical Co Ltd (XKRX:047920) » Definitions » 3-Year FCF Growth Rate

HLB Pharmaceutical Co (XKRX:047920) 3-Year FCF Growth Rate : -53.30% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is HLB Pharmaceutical Co 3-Year FCF Growth Rate?

HLB Pharmaceutical Co's Free Cash Flow per Share for the three months ended in Dec. 2023 was ₩-79.38.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -53.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -45.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of HLB Pharmaceutical Co was 53.90% per year. The lowest was -111.60% per year. And the median was -46.60% per year.


Competitive Comparison of HLB Pharmaceutical Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, HLB Pharmaceutical Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Pharmaceutical Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLB Pharmaceutical Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where HLB Pharmaceutical Co's 3-Year FCF Growth Rate falls into.



HLB Pharmaceutical Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


HLB Pharmaceutical Co  (XKRX:047920) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


HLB Pharmaceutical Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of HLB Pharmaceutical Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Pharmaceutical Co (XKRX:047920) Business Description

Traded in Other Exchanges
N/A
Address
67, Euiui-ro, Songpa-gu, MK Tower 9th Floor, Seoul, KOR
HLB Pharmaceutical Co Ltd is a research-oriented pharmaceutical company. It is engaged in developing medicines and drugs. Its products include skeletal muscle relaxant, pain relief drugs, blood pressure-lowering agents, local anaesthetics, digestive system drugs, antacids, vitamins, haemorrhoid solvents, insect repellents, peptic ulcer solvents, and other products.

HLB Pharmaceutical Co (XKRX:047920) Headlines

No Headlines